| Characteristic |
Total n=9,758 |
Deathsn(%) |
p value |
Male n=3,229 |
Deathsn(%) |
Female n=6,530 |
Deathsn(%) |
| Age-group (years) |
|
0.008* |
|
|
|
|
| 15-29 |
3,147 |
45(1.4) |
|
393 |
4(4.0) |
2,754 |
41(1.5) |
| 30-39 |
3,967 |
73(1.8) |
|
1,378 |
31(2.2) |
2,589 |
42(1.6) |
| 40-49 |
2,001 |
47(2.3) |
|
1,069 |
35(3.3) |
932 |
12(1.3) |
| 50+ |
644 |
16(2.5) |
|
389 |
9(2.3) |
255 |
7(2.7) |
| HBsAg status |
|
0.034 |
|
|
|
|
| HBsAg +ve |
1,950 |
48(2.5) |
|
721 |
25(3.5) |
1,230 |
23(1.9) |
| HBsAg –ve |
7,808 |
133(1.7) |
|
2,508 |
54(2.2) |
5,300 |
79(1.5) |
| Liver disease |
|
0.9 |
|
|
|
|
| Present |
23 |
0(0.0) |
|
5 |
0(0.0) |
18 |
0(0.0) |
| Absent |
9,728 |
181(1.9) |
|
3,220 |
79(2.5) |
6,508 |
102(1.9) |
| TB diagnosis |
|
<0.0001 |
|
|
|
|
| Present |
1,640 |
55(3.4) |
|
743 |
30(4.0) |
898 |
25(2.8) |
| Absent |
8,118 |
126(1.6) |
|
2,486 |
49(2.0) |
5,632 |
77(1.4) |
| HIV RNA at baseline (viral copies/mL) |
0.06* |
|
|
|
|
| <400 |
1,267 |
25(2.0) |
|
408 |
11(2.7) |
859 |
14(1.6) |
| 400-9,999 |
1,950 |
23(1.2) |
|
565 |
9(1.6) |
1,385 |
14(1.0) |
| 10,000-29,999 |
1,523 |
22(1.4) |
|
427 |
10(2.3) |
1,096 |
12(1.1) |
| ≥30,000 |
5,019 |
111(2.2) |
|
1,829 |
49(2.7) |
3,190 |
62(1.9) |
| CD4 cell count at baseline (cells/mL) |
0.003* |
|
|
|
|
| <200 |
1,599 |
24(1.5) |
|
605 |
7(1.2) |
994 |
17(1.7) |
| 200-499 |
1,050 |
4(0.4) |
|
295 |
1(0.3) |
755 |
3(0.4) |
| ≥500 |
136 |
0(0.0) |
|
24 |
0(0.0) |
112 |
0(0.0) |
| Period of enrolment |
<0.0001 |
|
|
|
|
| 2004-2006 |
5,920 |
143(2.4) |
|
1,963 |
67(3.4) |
3,958 |
76(1.9) |
| 2007-2010 |
3,838 |
38(1.0) |
|
1,266 |
12(0.9) |
2,572 |
26(1.0) |
*p values indicate comparison for trend |
